Why Summit Therapeutics (SMMT) Stock Rose 9.84% in 10 Minutes on Nov 16, 2026
The 9.84% gain was larger than any reaction MoveSurge measured after Summit Therapeutics headlines between Aug 18, 2026 and Nov 15, 2026; the largest of those was -0.68% in 10 minutes, on Oct 19, 2026.
- SMMT rose 9.84% in the 10 minutes after the 04:05:11 ET headline, from $10.47 to $11.50.
- 172,168 shares changed hands in those 10 minutes.
- The headline crossed in pre-market trading, 5 hours 25 minutes before the 9:30 ET open.
04:05:11 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| SMMT | 10.47 | 10.47 | 10.81 | 11.50 | +3.29% | +9.84% |
Summit Therapeutics (SMMT) shares rose 9.84% in the 10 minutes after this headline reached the MoveSurge news feed at 04:05:11 ET on Monday, November 16, 2026: “FDA declines approval of Summit Therapeutics' lung cancer drug”
SMMT in the first 10 minutes
From a reference price of $10.47 just before the headline, the stock was up 3.29% after one minute and up 9.84%, at $11.50, after 10 minutes. The move kept building after the first minute. 172,168 shares changed hands in those 10 minutes. The headline crossed in pre-market trading, 5 hours 25 minutes before the 9:30 ET open.
Earlier SMMT headlines and the measured reaction
The 9.84% gain was larger than any reaction MoveSurge measured after Summit Therapeutics headlines between Aug 18, 2026 and Nov 15, 2026; the largest of those was -0.68% in 10 minutes, on Oct 19, 2026.
- Oct 23, 2026, 16:37 ET: “Summit Therapeutics and Lunit agree to use AI-powered SCOPE IO pathology analysis to study tumor microenvironments for ivonescimab development” (+0.61% in 10 minutes)
- Oct 19, 2026, 07:03 ET: “Summit Therapeutics opens a global Phase II study of ivonescimab-based regimens for advanced clear cell renal cell carcinoma” (-0.68% in 10 minutes)
Summit Therapeutics at a glance
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Market value | $12.06 billion (as of Nov 16, 2026) |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
What headline moved Summit Therapeutics stock on November 16, 2026?
At 04:05:11 ET, this headline crossed: “FDA declines approval of Summit Therapeutics' lung cancer drug”. The stock rose 9.84% in the next 10 minutes.
How far did SMMT move after the headline?
From $10.47 just before the headline to $11.50 10 minutes later, a +9.84% move.
What else has moved SMMT stock recently?
The two largest measured reactions before November 16, 2026: Oct 19, 2026, Summit Therapeutics opens a global Phase II study of ivonescimab-based regimens for advanced clear cell renal cell carcinoma (-0.68% in 10 minutes); Oct 23, 2026, Summit Therapeutics and Lunit agree to use AI-powered SCOPE IO pathology analysis to study tumor microenvironments for ivonescimab development (+0.61% in 10 minutes).
Sources
-
SMMT headline and measured reaction, Nov 16, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Follow SMMT live
The live feed pairs breaking headlines with measured price moves. Build a watchlist of stocks you own and choose whether matching news reaches your WhatsApp.
Open the live feed See portfolio WhatsApp alerts